RxDoctor Payments Data

Jeffrey Manese, PA

Physician Assistant · San Francisco, CANPI 1619023769

Payments from drug & device makers

$1,802in general payments, 2019–2025

Across 47 payments — averaging $38.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$616
  • Medtronic$321
  • Neurocrine Biosciences, Inc.$203
  • MDD US Operations, LLC$176
  • Gilead$125
  • Teva Pharmaceuticals USA, Inc.$120
  • plus $241 from 8 others

What the payments were for

  • Speaking & faculty fees$261%
  • Travel & lodging$40%
  • Food & beverage$1,67493%
  • Education$985%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,802 in reported general payments places this provider in the 80th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$49,907
Medicare patients
179
Services billed
409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate43$325,956
RytaryCarbidopa/Levodopa196$228,699
InbrijaLevodopa45$162,263
OngentysOpicapone51$40,365
Carbidopa-Levodopa ErCarbidopa/Levodopa354$34,251
Carbidopa-LevodopaCarbidopa/Levodopa385$21,305
XadagoSafinamide Mesylate13$18,947
NeuproRotigotine15$15,194
Droxidopa20$15,182
Rasagiline Mesylate73$13,681
Entacapone36$7,435
Carbidopa16$6,592
Selegiline Hcl42$2,880
AmantadineAmantadine Hcl43$2,147
Donepezil Hcl112$1,389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$203$366,32294 claims
Amneal Pharmaceuticals LLCRytary$27$228,699196 claims
Acorda Therapeutics, IncInbrija$24$162,26345 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,423 physician assistant providers in California.

Other physician assistant in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →